Cover Image
市場調查報告書

腦啡肽酶:開發平台分析

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 359835
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
腦啡肽酶:開發平台分析 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 57 Pages
簡介

本報告提供以腦啡肽酶為標的的藥物之適應症,開發階段,作用機制,給藥途徑及各分子類型分析,提供您藥物的藥理作用相關記述,迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

腦啡肽酶概要

治療藥的開發

腦啡肽酶:開發中的產品 - 各開發階段

腦啡肽酶:開發中的產品 - 各治療範圍

腦啡肽酶:開發中的產品 - 各適應症

腦啡肽酶:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

腦啡肽酶:企業開發中的產品

腦啡肽酶:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

腦啡肽酶的治療藥開發企業

  • Novartis AG
  • Pharmaleads SA
  • Theravance Biopharma, Inc.

藥物簡介

腦啡肽酶:暫停中的計劃

腦啡肽酶:開發中止的產品

腦啡肽酶:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1061TDB

Summary:

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Neprilysin - Pipeline Review, H2, outlays comprehensive information on the Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Neprilysin also known as membrane metallo-endopeptidase (MME) is an enzyme that is encoded by the MME gene. Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P and bradykinin. It degrades the amyloid beta peptide whose abnormal misfolding and aggregation in neural tissue has been a cause of Alzheimer's disease. Inhibition of neprilysin helps in treatment of Pain and hypertension. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Metabolic Disorders and Gastrointestinal which include indications Chronic Heart Failure, Acute Heart Failure, Cancer Pain, Diabetic Nephropathy, Hypertension, Pain, Acute Pain, Alzheimer's Disease, Diabetic Neuropathic Pain, Migraine, Neuropathic Pain, Ocular Pain, Post-Myocardial Infarction and Resistant Hypertension.

Furthermore, this report also reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)
  • The report reviews Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Overview
    • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Companies Involved in Therapeutics Development
    • Bioprojet SCR
    • Novartis AG
    • Pharmaleads SA
    • Theravance Biopharma Inc
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Drug Profiles
    • (sacubitril + valsartan) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexecadotril - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LHW-090 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-265 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-37 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Neprilysin for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STR-324 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-0714 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-1439 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Dormant Products
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Discontinued Products
  • Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 19, 2017: New analysis shows Entresto improved physical and social activity in patients with HFrEF
      • Jun 29, 2017: Pharmaleads Reports Positive Phase I SAD Data with its Dual ENKephalinase Inhibitor PL265 for the Treatment of Neuropathic Pain
      • May 12, 2017: Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor, at the ARVO 2017 Annual Meeting
      • May 09, 2017: Novartis heart failure treatment Entresto (sacubitril/valsartan) now available to patients in Ontario through the public provincial drug plan
      • May 05, 2017: Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore
      • Mar 23, 2017: Novartis Pharmaceuticals Canada Announces Entresto now covered in Quebec
      • Mar 18, 2017: New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
      • Mar 09, 2017: Optimal use of Novartis heart failure treatment (Pr)Entresto could save more than 3,000 lives in Canada each year according to a new analysis
      • Jan 23, 2017: Positive Novartis drug trial using SphygmoCor XCEL
      • Nov 15, 2016: New analysis of Novartis' Entresto data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
      • Oct 25, 2016: Theravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714, an Inhibitor of Neprilysin (NEP)
      • Sep 19, 2016: Important new analysis shows that Novartis Entresto is associated with higher relative health-related quality of life scores among HFrEF patients
      • Jun 22, 2016: Timely use of Novartis Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
      • Jun 09, 2016: New Review of PARADIGM-HF Results: LCZ696, an Angiotensin-neprilysin Inhibitor, Versus Enalapril in Heart Failure
      • May 21, 2016: Novartis' Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Bioprojet SCR, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Pharmaleads SA, H2 2017
  • Pipeline by Theravance Biopharma Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top